Reliance Global Group Inc SEC Filings

Reliance Global Group, Inc. filed an initial ownership report (Form 3) for Zackary Andrew Wilder, who serves as Chief Technology Officer. The filing does not list any reportable common stock or derivative transactions, indicating this is a baseline disclosure of insider status rather than a record of trades.

Reliance Global Group, Inc. executive Judah Korman, the Chief Operating Officer, has filed an initial Form 3 insider ownership report for ticker EZRA. This filing establishes his status as a reporting person under SEC rules and does not report any recent insider trades in the provided data.

Reliance Global Group announced several leadership moves and equity awards tied to its AI-focused insurance strategy. The Board appointed Judah Korman as Chief Operating Officer and Zack Wilder as Chief Technology Officer, and promoted Mordy Beyman to Vice President, all effective June 18, 2026. Korman and Beyman are immediate family members of current directors, so their compensation packages were treated as related party transactions and approved by disinterested directors.

Korman will receive a $300,000 base salary and a $300,000 annual equity award, with an initial grant of 21,941 restricted shares vesting between July and September 2026. Wilder is set to receive a $300,000 base salary and a $300,000 restricted stock award under the 2025 Equity Incentive Plan. Beyman’s new package includes a $150,000 salary and a $150,000 equity award, with an initial 7,314 restricted shares vesting on the same schedule.

The Compensation Committee also set CEO Ezra Beyman’s 2026 pay at a $513,000 salary, a $593,000 target cash bonus, a fully vested stock award valued at $1,058,000 under the 2025 Plan, and a $45,000 annual life insurance premium. On June 24, 2026, the Committee granted restricted stock to directors and officers, including 151,575 shares to the CEO, at a grant-date price of $3.455 per share, as part of a broader program to align leadership with Reliance’s AI-powered agency roll-up and AI-native insurance product initiatives.

Reliance Global Group, Inc. has regained compliance with Nasdaq’s continued listing rules after its stock met the exchange’s minimum bid price requirement. Nasdaq confirmed that the company’s common stock closed at or above $1.00 per share for 10 consecutive business days from May 18, 2026 through June 1, 2026, resolving a prior deficiency notice issued in December 2025. The company remains listed on the Nasdaq Capital Market and highlighted ongoing efforts to expand its Insurtech platforms and EZRA International Group while pursuing long-term shareholder value.

Reliance Global Group, Inc. approved and implemented a 1-for-40 reverse stock split of its common stock to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement. The amendment to the articles of incorporation is scheduled to become effective at 5:00 p.m. Eastern on May 15, 2026.

Every 40 existing shares will convert into one share, reducing the amount of common stock outstanding from approximately 22,230,563 shares to 555,764 shares, while authorized common shares will be set at 50 million and par value stays at $0.086 per share. Trading on a split-adjusted basis on the Nasdaq Capital Market under the symbol EZRA and new CUSIP 75946W504 is expected to begin on May 18, 2026, with each shareholder’s ownership percentage remaining the same.

Reliance Global Group (Nasdaq: EZRA) reported a first‑quarter 2026 net loss of $1.47 million, narrowing from $1.74 million a year earlier, as it continued reshaping its portfolio and cost structure. Commission revenue declined about 10% to $3.83 million, mainly due to selling several agencies in 2025, partly offset by roughly 11% organic growth in remaining businesses.

Operating expenses fell to $5.07 million from $5.64 million, but non‑GAAP AEBITDA turned to a loss of $0.43 million from a positive $0.15 million, largely because equity‑based compensation was much lower in 2026 and therefore added back less. Cash and restricted cash rose to $3.24 million with working capital of about $2.60 million and stockholders’ equity of $7.42 million.

The company invested about $0.50 million in Enquantum, taking a roughly 23.8% stake and recording an equity‑method loss of about $26,000. It also completed a public offering providing roughly $2.0 million in gross proceeds and realized about $0.84 million from warrant exercises, while modestly using its at‑the‑market program.

Subsequent to quarter‑end, Reliance formed majority‑owned LifeSci Global Group to invest about $2.0 million in Innervate Radiopharmaceuticals and expanded its equity line of credit to $50.0 million, with about $49.1 million remaining. The board approved a 1‑for‑40 reverse stock split to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement, highlighting listing risk alongside the company’s push into technology and life sciences through its EZRA International Group and Scale51 strategy.

Reliance Global Group, Inc. reported results from its 2026 Annual Meeting of Stockholders, held via live webcast. As of March 5, 2026, there were 21,253,013 common shares outstanding and entitled to vote, and 9,591,634 shares were represented, about 45.13% of those eligible.

Stockholders elected five directors to serve until the 2027 annual meeting and ratified Urish Popeck & Co., LLC as independent auditor for the year ending December 31, 2026. Each director nominee received over 3.27 million votes for, with substantial broker non-votes.

Investors also approved an amendment to the 2025 Equity Incentive Plan, increasing shares available for issuance by 14,000,000, from 2,000,000 to 16,000,000. In a separate proposal, stockholders approved issuing common shares in excess of the Nasdaq Exchange Cap under a Common Stock Purchase Agreement dated August 26, 2025, as amended.

Reliance Global Group formed LifeSci Global Group LLC, a majority-owned healthcare investment vehicle, and funded it using a Promissory Note of up to $2,000,000 from its subsidiary EZRA International Group.

LifeSci Global agreed to purchase up to 421,053 Innervate Radiopharmaceuticals units at $4.75 per unit, totaling about $2.0 million, with $500,000 funded at closing. The deal includes priority distributions and up to 210,526 warrants and was approved by independent directors as a related-party transaction, with committee reshuffling to ensure board independence.

Reliance Global Group, Inc. filed a post-effective prospectus supplement updating its registration to cover the securities issued in its January 29, 2026 public financing and the ongoing issuance of shares upon exercise of related warrants. The January 2026 Offering sold 7,219,259 shares, 188,149 pre-funded warrants, 14,814,816 common warrants and issued 518,519 placement agent warrants at a combined public offering price of $0.27 per unit (or $0.269 per pre-funded unit), generating gross proceeds of approximately $2.0 million. The prospectus registers up to 15,521,484 shares issuable upon exercise of the issued warrants, and summarizes exercise terms (common warrant exercise price $0.27, pre-funded warrant exercise price $0.001, placement agent warrant exercise price $0.3375) and related transfer, beneficial-ownership limitations and cashless-exercise provisions.

The filing also discloses recent corporate developments including the launch of EZRA International/Scale51, a staged equity investment in Enquantum (16% ownership to date, target 51% via milestone tranches), amendments expanding an equity line commitment to $50.0 million, repayment of approximately $5.0 million of long-term debt in 2025, adoption of a digital asset treasury strategy, and corporate governance updates (restated articles and amended bylaws). The company’s Nasdaq ticker changed to EZRA and the last reported sale price on April 28, 2026 was $0.1753 per share.